Neurocrine shareholders approve amended 2020 equity plan and elect directors at 2023 annual meeting

Approval of the Amended 2020 Plan. Shares Voted: For 69,250,973 Against 12,198,955 Abstain 72,654 Percent of Voted: For 84.95 % Against 14.96 % There were 5,004,423 broker non-votes for this proposal. The Amended 2020 Plan was approved.

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. Shares Voted: For 80,314,052 Against 6,163,365 Abstain 49,588 Percent of Voted: For 92.82 % Against 7.12 % The appointment of Ernst & Young LLP was ratified.

An advisory vote on the frequency of advisory voting on the compensation paid to the Company's named executive officers. Shares Voted: 1 Year 80,717,040 2 Years 23,501 3 Years 725,957 Abstain 56,084 Percent of Voted: 1 Year 99.01 % 2 Years 0.03 % 3 Years 0.89 % There were 5,004,423 broker non-votes for this proposal. In light of this result, the Company will hold future say on pay votes on an annual basis until the next advisory vote on the frequency of say on pay votes occurs.

Election of three Class III Directors for a term of three years expiring at the 2026 Annual Meeting of Stockholders. Kevin C. Gorman, Ph.D. For 79,212,382 Withheld 2,310,200 Gary A. Lyons For 67,873,034 Withheld 13,649,548 Johanna Mercier For 73,442,103 Withheld 8,080,479 There were 5,004,423 broker non-votes for this proposal. The three nominees for Class III Director were elected.

An advisory vote on the compensation paid to the Company's named executive officers. Shares Voted: For 75,903,905 Against 5,557,583 Abstain 61,094 Percent of Voted: For 93.11 % Against 6.82 % There were 5,004,423 broker non-votes for this proposal. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.